TetraLogic Pharmaceuticals Corp (TLOG) 收益

TetraLogic Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel small molecule therapeutics in oncology and infectious diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 29 full-time employees. The company went IPO on 2013-12-12. The firm is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The firm's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The firm has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The firm is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.